

01
02 MARCH 2018
Madrid

VISION & INNOVATION

IN
GYNECOLOGICAL
CANCER

1st University of
Navarra International
Educational Meeting

Chairmen: **Dr. Luis Chiva**, Clínica Universidad de Navarra, Madrid, Spain
Dr. Antonio González Martín, Clínica Universidad de Navarra, Madrid, Spain

Organized by:



Clínica
Universidad
de Navarra

FACULTY

- Giovanni Aletti.** Istituto Europeo di Oncologia, Milan, Italy
Susana Banerjee. Royal Marsden, London, UK
David Cibula. Charles University Hospital, Prague, Czech Republic
Nicoletta Colombo. Istituto Europeo di Oncologia, Milan, Italy
Andreas Du Bois. Klinik für Gynäkologie & Gynäkologischer Onkologie, Essen, Germany
Christina Fotopoulou. Imperial College Healthcare NHS Trust, London, UK
Matías Jurado. Clínica Universidad de Navarra, Pamplona, Spain
Jonathan Ledermann. UCL Cancer Institute at University College, London, UK
Domenica Lorusso. Instituto Nazionale Dei Tumori, Milan, Italy
Christian Marth. Innsbruck Medical University , Austria
Sergi Martínez. ICO-Germans Trias i Pujol, Barcelona, Spain
Ignacio H. Medrano. Savana Company Founder, Madrid, Spain
José A. Mínguez. Clínica Universidad de Navarra, Pamplona, Spain
Mansoor Mirza. Copenhagen University Hospital, Denmark
Philippe Morice. Institut Gustave Roussy, Paris, France
Ana Oakenin. Hospital Universitario Vall d'Hebron, Barcelona, Spain
Sandro Pignata. IRCCS National Cancer Institute "Fondazione G. Pascale", Naples, Italy
Jordi Ponce. Hospital Univ. Bellvitge, Barcelona, Spain
Andrés Poveda. Instituto Valenciano de Oncología (IVO), Valencia, Spain
Eric Pujade-Lauraine. Centre Hospitalier Universitaire Hôtel-Dieu, Paris, France
Isabelle Ray-Coquard. Université Lyon, France
Andrés Redondo. Hospital Universitario La Paz, Madrid, Spain
Luisa Sánchez. Clínica Universidad de Navarra, Madrid, Spain
Jalid Sehouli. Charité Universitätsmedizin Berlin, Germany
Ignace Vergote. University Hospitals Leuven, Belgium

LOCAL COMMITTEE

Gynecology

Teresa Castellanos
José A. Mínguez
Matías Jurado
Santiago Lizarraga
Daniel Vázquez

Oncology

José Manuel Aramendía
Jaimé Espinós
Luisa Sánchez

Radiation Oncology

Felipe Calvo
Mauricio Cambeiro

Radiology

Alberto Alonso
Víctor Manuel Suárez
Meylin Caballeros

Pathology

Íñigo Espinosa
Miguel Ángel Idoate

Nuclear Medicine

Lidia Sancho
Fernando Guillén

VISION & INNOVATION IN GYNECOLOGICAL CANCER

1st University of
Navarra International
Educational Meeting

THURSDAY, MARCH 1ST 2018

08:30-09:00 Registration and Welcome

Luis Chiva. Clínica Universidad de Navarra, Madrid, Spain

Antonio González-Martín. Clínica Universidad de Navarra, Madrid, Spain

09:00-11:00 Vision in Newly Diagnosed Advanced Ovarian Cancer: from Concept to the Clinic

Moderator

Luis Chiva. Clínica Universidad de Navarra, Madrid, Spain

Keynote Lecture on State of the Art. Goals and Limits of Surgery in Advanced Ovarian Cancer: Have we reached our Finish Line?

Andreas Du Bois. Klinik für Gynäkologie & Gynäkologischer Onkologie, Essen, Germany

Panel Discussion

Panelists will discuss the following topics on daily clinical practice: how to assess resectability, surgery for stage IV, is there any role for HIPEC?, role of lymphadenectomy, is minimal residual disease (0.1-1 cm) still a surgical goal?, ERAS implementation, quality indicators in upfront surgery and how to improve surgical skills in young surgeons.

Giovanni Aletti. Istituto Europeo di Oncologia, Milan, Italy

Andreas Du Bois. Klinik für Gynäkologie & Gynäkologischer Onkologie, Essen, Germany

Christina Fotopoulou. Imperial College Healthcare NHS Trust, London, UK

Philippe Morice. Institut Gustave Roussy, Paris, France

Sergi Martinez. ICO-Germans Trias i Pujol, Barcelona, Spain

Jalid Sehouli. Charité Universitätsmedizin Berlin, Germany

11:00-11:30 Coffee break

11:30-13:30 **Innovation in Newly Diagnosed Advanced Ovarian Cancer:
The Challenge of Designing New Trials in Front Line**

Moderator

Antonio González-Martín. Clínica Universidad de Navarra, Madrid, Spain

Keynote Lecture: New Trials with Systemic Therapy in Front Line

Sandro Pignata. IRCCS National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Panel Discussion

The design of new trials with systemic therapy in this era is challenging and may impact the interpretation of the results in the future as well as the implementation in the clinic. Some points of discussion may focus on: the impact of postoperative CT scan in patient selection, is it worthwhile to explore HRD or just the BRCA status, the inclusion of optimally debulked patients, inclusion of bevacizumab as physician choice versus mandatory, limit or not the rate of interval debulking surgery, the absence of phase I/II data for some of the combinations, adaptive models depending on results of ongoing trials as ENGOT ov-16 (PRIMA) or SOLO-1, and how to include biomarker research.

Andreas Du Bois. Klinik für Gynäkologie & Gynäkologischer Onkologie, Essen, Germany

Domenica Lorusso. Instituto Nazionale Dei Tumori, Milan, Italy

Sandro Pignata. IRCCS National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Eric Pujade-Lauraine. Centre Hospitalier Universitaire Hôtel-Dieu, Paris, France

Isabelle Ray-Coquard. Université Lyon, France

Ignace Vergote. University Hospitals Leuven, Belgium

13:30-15:00 **Lunch**

15:00-15:30 **Breakthrough Lecture**

Moderators

Luis Chiva. Clínica Universidad de Navarra, Madrid, Spain

Antonio González-Martín. Clínica Universidad de Navarra, Madrid, Spain

Looking to the future: How Big Data Captured from Unstructured Information will Change our Clinical and Research Practice

Ignacio H. Medrano. Savana Company Founder, Madrid, Spain

**15:30-16:30 Innovation in Early Relapse Ovarian Cancer:
Facing the Patient for whom Platinum is not an Option**

Moderator

Mansoor Mirza. Copenhagen University Hospital, Denmark

Keynote Lecture: New Drugs, Designs and Endpoints in Clinical Trials

Ignace Vergote. University Hospitals Leuven, Belgium

Panel Discussion

Patients for whom platinum is no longer an option became a challenge in our clinical practice. Fortunately, a plethora of new drugs are coming. However, a wise balance between offering innovative trials and facing end of life, as well as the refinement of patient-reported outcome tools are needed for this population of patients.

Susana Banerjee. Royal Marsden, London, UK

Domenica Lorusso. Istituto Nazionale Dei Tumori, Milan, Italy

Christian Marth. Innsbruck Medical University, Austria

Ana Oznin. Hospital Universitario Vall d'Hebron, Barcelona, Spain

Ignace Vergote. University Hospitals Leuven, Belgium

16:30-17:00 Coffee break

17:00-18:30 Vision in Late Relapse Ovarian Cancer: From Randomized Trials to Clinic in Patient for whom Platinum is still an Option

Moderator

Jonathan Ledermann. UCL Cancer Institute at University College, London, UK

Keynote Lecture: Options for Patients when Platinum is an Option

Christian Marth. Innsbruck Medical University, Austria

Panel Discussion

The landscape for the management of patients with late relapse ovarian cancer has evolved in the last few years with the upcoming of antiangiogenics first and nowadays with the clinical data on secondary debulking and especially with three PARP inhibitors. This amazing moment with so many options must lead to a deep reflection on patient selection and the best timing for the different strategies.

Andreas Du Bois. Klinik für Gynäkologie & Gynäkologischer Onkologie, Essen, Germany

Nicoletta Colombo. Istituto Europeo di Oncologia, Milan, Italy

Christian Marth. Innsbruck Medical University , Austria

Mansoor Mirza. Copenhagen University Hospital, Denmark

Eric Pujade-Lauraine. Centre Hospitalier Universitaire Hôtel-Dieu, Paris, France

Ignace Vergote. University Hospitals Leuven, Belgium

18:30 Closing Remarks

FRIDAY, MARCH 2ND 2018

08:30-10:30 Board of Rare Gynecological Tumors and Endometrial Cancer

Moderator

Andrés Poveda. Instituto Valenciano de Oncología (IVO), Valencia, Spain

Case Presenters

Matías Jurado. Clínica Universidad de Navarra, Pamplona, Spain

José A. Mínguez. Clínica Universidad de Navarra, Pamplona, Spain

Jordi Ponce. Hospital Univ. Bellvitge, Barcelona, Spain

Andrés Redondo. Hospital Universitario La Paz, Madrid, Spain

Luisa Sánchez. Clínica Universidad de Navarra, Madrid, Spain

Panel Discussion

Management of rare tumors is lacking of good evidence for guiding daily clinical practice. On the other hand, some situations in endometrial cancer are still a matter debate despite several randomized clinical trials. The tumor board will be an opportunity for the discussion of different options of challenging cases.

Susana Banerjee. Royal Marsden, London, UK

David Cibula. Charles University Hospital, Prague, Czech Republic

Nicoletta Colombo. Istituto Europeo di Oncologia, Milan, Italy

Christina Fotopoulou. Imperial College Healthcare NHS Trust, London, UK

Jonathan Ledermann. UCL Cancer Institute at University College, London, UK

Philippe Morice. Institut Gustave Roussy, Paris, France

Jalid Sehouli. Charité Universitätsmedizin Berlin, Germany

10:30-11:00 1st Clínica Universidad de Navarra Award to a Career Devoted to Gynecological Cancer

11:00-11:30 Coffee break

11:30-13:30 Vision and Innovation in Cervical Cancer

Moderator

Ana Oakenin. Hospital Universitario Vall d'Hebron, Barcelona, Spain

Keynote Lecture: What is Coming in Cervical Cancer?

Nicoletta Colombo. Istituto Europeo di Oncologia, Milan, Italy

Panel Discussion

The outcome of many locally advanced and the majority of recurrent cervical cancer patients is still poor and full of limitations. Several approaches are still under debate or investigation. Some of them as sentinel node biopsy, neoadjuvant chemotherapy, adjuvant therapy after radical therapy of locally advanced disease, surgery of recurrent disease, patient selection for bevacizumab and the promise of the immunotherapy will be addressed by the panel.

Giovanni Aletti. Istituto Europeo di Oncologia, Milan, Italy

David Cibula. Charles University Hospital, Prague, Czech Republic

Domenica Lorusso. Istituto Nazionale Dei Tumori, Milan, Italy

Nicoletta Colombo. Istituto Europeo di Oncologia, Milan, Italy

Jordi Ponce. Hospital Univ. Bellvitge, Barcelona, Spain

Ignace Vergote. University Hospitals Leuven, Belgium

13:30

Closing Remarks

Luis Chiva. Clínica Universidad de Navarra, Madrid, Spain

Antonio González-Martín. Clínica Universidad de Navarra, Madrid, Spain



Under the auspices of:



SeAP-IAP
[Sociedad Española de Anatomía Patológica]
(International Academy of Pathology)



SEOM
Sociedad Española
de Oncología Médica

SEOR
SOCIEDAD ESPAÑOLA DE
ONCOLOGÍA RADIOTERÁPICA

Accreditation:

Continuing Education Credits (CFC) requested to the Spanish National Health System.
Full attendance to the meeting will be required in order to receive credits

Venue:

Rafael del Pino Auditorium
Calle Rafael Calvo, 39A
28010 Madrid (Spain)

Meeting Secretariat:



Tel.: +34 91 372 0203 · e - mail: CUN_gyn@doctaforum.com
www.cun.es/vision-innovation-gynecological-cancer